BMJ Open

Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study

Lu-Dong Qiao,1 Shan Chen,1 Yong Yang,2 Kai Zhang,3 Bo Zheng,4 Hong-Feng Guo,5 Bo Yang,6 Yuan-Jie Niu,7 Yi Wang,8 Ben-Kang Shi,9 Wei-Min Yang,10 Xiao-Kun Zhao,11 Xiao-Feng Gao,12 Ming Chen,13 Ye Tian14

ABSTRACT

Objective: This study assessed the characteristics of pathogens identified in clinical isolates from patients with urinary tract infection (UTI) and their in vitro sensitivity to commonly used antibiotics in the clinical setting in China.

Design and setting: Multicenter study was conducted between January and December 2011 in 12 hospitals in China.

Participants: Urine samples were collected from 356 symptomatic patients treated in the study hospitals for acute uncomplicated cystitis, recurrent UTI or complicated UTI.

Primary and secondary outcome measures: Minimal inhibitory concentrations (MICs) were measured using broth microdilution according to the Clinical and Laboratory Standards Institute 2011 guidelines. Thirteen antimicrobial agents were tested: fosfomycin tromethamine, levofloxacin, moxifloxacin, cefdinir, cefixime, cefaclor, cefprozil, cefuroxime, amoxicillin/clavulanic acid, cefotaxime, azithromycin, nitrofurantoin and oxacillin. Escherichia coli isolates were screened and extended spectrum β-lactamases (ESBL) production was confirmed by a double-disk synergy test.

Results: 198 urine samples were culture-positive and 175 isolates were included in the final analysis. E coli was detected in 50% of cultures, followed by Staphylococcus epidermidis (9%), Enterococcus faecalis (9%) and Klebsiella pneumoniae (5%). The detection rate of ESBL-producing E coli was 53%. Resistance to levofloxacin was the most common among all the isolates. Nitrofurantoin and fosfomycin tromethamine had the greatest activity against E coli; overall, 92% and 91% of isolates were susceptible to these antimicrobials. E faecalis had the highest susceptibility rates to fosfomycin tromethamine (100%).

Conclusions: The most frequently identified pathogens in our patients were ESBL-producing E coli and E faecalis. Fosfomycin tromethamine and nitrofurantoin showed a good antimicrobial activity against UTI pathogens. They may represent good options for the empiric treatment of patients with UTI.

Strengths and limitations of this study

▪ This study was conducted in 12 major clinical research centres from China. Antibiotic susceptibility was tested with 13 antimicrobial agents that are frequently used in the clinical practice in China.

▪ A strength of the study is correct subspecialisation of coagulase negative staphylococci, enterococci and streptococci.

▪ For several pathogens, due to the relatively low number of tested isolates, differences in susceptibility patterns between various urinary tract infection (UTI) types could not be assessed. No distinction was made between community-acquired and healthcare-associated UTIs.

INTRODUCTION

Urinary tract infections (UTIs) are common infectious diseases in clinical practice. An estimated 150 million people worldwide are diagnosed with a UTI each year,1 and 40–50% of women present a UTI at least once in their lifetime.2–5 The results of a survey performed in the USA estimated that a UTI episode was associated with an average of 6.1 days with symptoms, 2.4 days of reduced activity and 0.4 days of bed rest, thus generating an estimated annual cost (direct and indirect) of 1.6 billion dollars.6–8 In China, UTIs account for 9.99–50% of nosocomial infections.9 10 Most cases of UTI are caused by Gram-negative bacilli, with Escherichia coli accounting for over 90% of uncomplicated UTIs.11 Uncomplicated infections can be treated with short courses of antibiotics, while complicated UTIs require longer and more intensive courses of antibiotics. However, resistance to the commonly used antibiotics is increasing and making treatment more difficult.
In China, clinical isolates of *E coli* have been shown to have resistance rates as high as 20.6–27.9% to amoxicillin/ clavulanic acid, 64.7–74% to ciprofloxacin and 71.1–80.1% to piperacillin.  

Many cases in which UTIs are resistant to conventional treatment have been associated with *E coli* isolates producing extended spectrum β-lactamas (ESBLs). The emergence of these ESBL-producing isolates makes clinical treatment even more difficult. This study assesses the distribution of pathogens of acute uncomplicated cystitis, recurrent UTI or complicated UTI and their in-vitro sensitivity to commonly used antibiotics in the clinical treatment of these infections. These findings will be informative for physicians in their decision-making in empirical medicine, thus contributing to the prevention and mitigation of the increase in drug resistance.

**PATIENTS AND METHODS**

**Source of isolates**

Enrolled patients were between 18 years old and 70 years old, suffered from acute uncomplicated cystitis, recurrent UTI or complicated UTI, were symptomatic and were treated in the urology department in 1 of 12 clinical research centres between 26 January and 7 December 2011. The study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Beijing Tongren Affiliated Hospital of Capital Medical University. The study patients signed an informed consent form before any study procedure was conducted. Midstream urine specimens for bacterial culture were collected before treatment. Colony counts higher than or equal to $10^5$ colony forming units (CFU)/mL were considered significant.

**Antibiotics and reagents**

The following antimicrobial agents were used for susceptibility testing: oxacillin, amoxicillin, cefaclor, cefuroxime and nitrofurantoin, obtained from the National Institute for Food and Drug control (Beijing, China); levofloxacin from Daiichi Sankyo (Beijing, China); moxifloxacin and fosfomycin tromethamine produced by Shanxi Qianyuan Pharmaceutical Co., Ltd (Shanxi, China); cefdinir from Jinkang, Tianjin Pharmaceutical Group (Tianjin, China); cefixime from Guangzhou Baiyunshan Pharmaceutical Factory (Guangzhou, China); cefprozil from Bristol-Myers Squibb (Shanghai, China); cefotaxime from Sanjiu Group Shenzhen Jiuxin Pharmaceutical Co., Ltd (Shenzhen, China); azithromycin from Pfizer (Dalian, China) and clavulanic acid from GlaxoSmithKline (Tianjin, China).

The amoxicillin/clavulanic acid combination was used at a ratio of 2:1. For the cefotaxime/clavulanic acid combination, clavulanic acid concentration was kept constant at 4 μg/L. Susceptibility medium (Mueller-Hinton (MH)), cefazidine (CAZ, 30 μg) (used to detect ESBLs), amoxicillin/clavulanic acid (AMC, 20 μg/10 μg) and cefotaxime (CTX, 30 μg) susceptibility paper disks were purchased from Thermo Fisher Biochemicals (Beijing) Ltd (Beijing, China).

**Tested isolates**

The sensitivity test was标准化 using the following reference isolates: *Staphylococcus aureus* ATCC 29213, *E faecalis* ATCC 29212, *E coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853, originating from the American-type culture collection.

Clinical isolates were identified in the urine samples collected in the clinical research centres participating in the study. Medium and incubation conditions: *S aureus*, *Enterococcus* spp and Gram-negative bacteria were incubated in MH medium at 35°C for 16–20 h. Susceptibility of staphylococci to oxacillin was assessed using MH agar supplemented with 2% NaCl solution, and 24 h additional incubation. Streptococci were incubated in blood culture medium (5% defibrinated sheep blood added to MH medium) at 35°C in 5% CO₂ (CO₂ incubator) for 20–24 h.

**Minimum inhibitory concentration measurement**

For minimal inhibitory concentration (MIC) measurement, a standard plate count and double dilution method was used. Bacterial suspensions to be tested were prepared by inoculation with $10^3$ CFU of each bacterium, using a multipoint inoculator. The MIC of the antimicrobial agents was measured for a variety of pathogens.

**Processing of the results**

MIC50 and MIC90 values were calculated, as well as the bacterial resistance rate, the intermediate rate and the sensitivity rate according to the critical concentration standards for antimicrobial drugs promulgated by the Clinical and Laboratory Standards Institute in 2011.  

ESBL-producing *E coli*, *Klebsiella pneumoniae* and *Proteus mirabilis* were identified using a double-disc synergy test.

**RESULTS**

**Distribution of isolates**

A total of 356 patients were enrolled and provided a urine sample. Of these, 198 (55.6%) tested positive for significant bacteriuria. In 23 urine samples, the clinical pathogens could not be identified without performing additional tests and were excluded from the analysis. A total of 175 isolates with identified pathogens were included in the final analysis: 116 (66.3%) Gram-negative bacteria and 59 (33.7%) Gram-positive bacteria. *E coli* was the most frequently identified Gram-negative bacteria (in 87 isolates (49.7%)). The most frequently identified Gram-positive pathogens were: *Staphylococcus* spp (in 30 isolates (17.1%)), *Enterococcus* spp (in 19 isolates (10.9%)) and *Streptococcus* spp (in 10 isolates (5.7%)); table 1).

Of the 175 isolates, 124 (70.9%) were from women, with *E coli* and *K pneumoniae* being the most frequently identified. In men, the most frequently identified pathogens were *E coli* and *E faecalis* (table 2).

Ninety-five isolates were from patients with acute uncomplicated cystitis, 42 from patients with recurrent UTIs and 37 from patients with complicated UTIs (table 3).
**E. coli** antibiotic resistance

Of the 87 **E. coli** isolates, 49.4% were resistant to levofloxacin, 50.6% were resistant to second-generation cephalosporin and 57.5% to third-generation cephalosporin. Forty-six **E. coli** isolates (52.9%) were ESBL producers (Table 4).

Nitrofurantoin and fosfomycin tromethamine had the greatest activity against **E. coli**; overall, 92% and 91% of isolates were susceptible to these antimicrobials. The percentages of isolates positive for **E. coli** by UTI type, and the proportion of ESBL-producing isolates are presented in Table 3.

**Susceptibility results for K. pneumoniae and Proteus spp**

Overall, nine isolates were identified as **K. pneumoniae** (5.1%) and nine as **Proteus** bacilli (5.1%). The corresponding susceptibility results are presented in Table 5.

**Antibacterial activity of commonly used antibiotics against coagulase-negative staphylococci and E. faecalis**

For coagulase-negative staphylococci, sensitivity rates ranged from 38.5% for oxacillin to 100% for nitrofurantoin and resistance rates from 0% for nitrofurantoin to 84.6% for azithromycin. For **Staphylococcus epidermidis**, sensitivity rates ranged from 18.8% for azithromycin to 100% for nitrofurantoin and fosfomycin tromethamine; and resistance rates ranged from 0% for nitrofurantoin and fosfomycin tromethamine to 81.2% for azithromycin. The resistance rate of **E. faecalis** against levofloxacin was 60%, while the sensitivity rate to fosfomycin tromethamine and nitrofurantoin was 100%. MIC values for these pathogens are presented in Table 6.

**DISCUSSION**

We demonstrated that, in Chinese patients with symptomatic UTI enrolled from research hospitals, **E. coli** was the most frequent pathogen identified in men and women, accounting for 49.7% of the total isolates. Other pathogens identified were **S. epidermidis** (9.1%), **E. faecalis** (8.6%), **K. pneumoniae** (5.1%) and **P. mirabilis** (3.4%). The results obtained in this study are similar to those of other studies conducted in China. Although **E. coli** was the leading cause of UTI in men, its proportion was lower than in women. The prevalence of **E. faecalis**

---

**Table 1** Number and proportion of isolated pathogens from midstream urine species

| Gram-negative bacteria | Gram-positive bacteria |
|------------------------|------------------------|
| **Bacterium**           | **N** | **Per cent** | **Bacterium** | **N** | **Per cent** |
| **Escherichia coli**    | 87    | 49.71        | **Staphylococcus aureus** | 4 | 2.29 |
| **Klebsiella pneumoniae** | 9 | 5.14        | **Staphylococcus epidermidis** | 16 | 9.14 |
| **Proteus mirabilis**   | 6     | 3.43         | **Staphylococcus hominis** | 5 | 2.86 |
| **Proteus vulgaris**    | 2     | 1.14         | **Staphylococcus saprophyticus** | 2 | 1.14 |
| **Proteus penneri**     | 1     | 0.57         | **Staphylococcus haemolyticus** | 1 | 0.57 |
| **Enterobacter cloacae** | 2 | 1.14         | **Staphylococcus schleiferi** | 1 | 0.57 |
| **Citrobacter freundii** | 2 | 1.14         | **Staphylococcus warneri** | 1 | 0.57 |
| **Citrobacter koseri**  | 1     | 0.57         | **Enterococcus faecalis** | 15 | 8.57 |
| **Serratia marcescens** | 1     | 0.57         | **Enterococcus faecium** | 3 | 1.71 |
| **Pseudomonas aeruginosa** | 4 | 2.29         | **Enterococcus gallinarum** | 1 | 0.57 |
| **Pseudomonas putida**  | 1     | 0.57         | **Streptococcus agalactiae** | 5 | 2.86 |
| **Pseudomonas putida**  | 1     | 0.57         | **Streptococcus oralis** | 2 | 1.14 |
| **Pseudomonas putida**  | 1     | 0.57         | **Streptococcus acidominimus** | 1 | 0.57 |
| **Pseudomonas putida**  | 1     | 0.57         | **Streptococcus haemolyticus** | 1 | 0.57 |
| **Pseudomonas putida**  | 1     | 0.57         | **Streptococcus mitis** | 1 | 0.57 |

*Percentages are computed on a total of 175 isolates.

n, number of isolates analysed; N, number of isolates within a category.

---

**Table 2** The distribution of pathogens in patients according to gender

| **Bacteria** | **Women Number of patients** | **Men Number of patients** |
|--------------|------------------------------|---------------------------|
| **Escherichia coli** | 68 | 54.84 | 19 | 37.25 |
| **Klebsiella pneumoniae** | 9 | 7.26 | 0 | 0 |
| **Staphylococcus epidermidis** | 10 | 8.06 | 6 | 11.76 |
| **Enterococcus faecalis** | 5 | 4.03 | 10 | 19.61 |
| **Others** | 32 | 2.58 | 16 | 3.14 |
| **Total** | 124 | 51 | | |
infections was higher in men than in women. The infection rate with Gram-negative bacteria was higher in patients with uncomplicated cystitis than in patients with recurrent or complicated UTI, while the infection rate with Gram-positive bacteria showed an inverse trend.

*E. coli* is the most common Gram-negative bacteria identified in UTIs. An important mechanism of antibiotic resistance among pathogens is through ESBL production. ESBL hydrolyses oximino-β-lactams such as cephalosporin and monobactum. *E. coli* is one of the main ESBL-producing pathogens. ESBL production is transmitted from one bacterium to another through plasmids. These plasmids can carry multiple drug-resistant genes against aminoglycosides, quinolones and sulfamethoxazole at the same time. The phenomenon of multidrug resistance has brought tremendous difficulties to the clinical treatment of infection due to limited therapeutic options. Haishen et al. showed that ESBL-producing *E. coli* have a high resistance rate, ranging from 28.6% to 85.7% against the majority of antibiotics (excluding sulfaframethoxazole), which is 20% to 80% higher than in *E. coli* that do not produce ESBLs.

An increasing prevalence of ESBL-positive bacteria isolated from UTI patients has made the empirical treatment of these diseases difficult. Consequently, carbapenems have been increasingly prescribed as an empirical treatment for complicated UTIs, thus promoting the selection of drug-resistant bacteria and an increased prevalence of flora imbalance and fungal infections. In our study, the proportion of *E. coli* varied with the UTI type: the prevalence of *E. coli* overall and of ESBL-producing *E. coli* was lower in isolates from cases diagnosed with acute uncomplicated cystitis, compared with recurrent and complicated UTIs. The prevalence of ESBL-producing *E. coli* reached 60% in isolates from cases diagnosed with complicated UTI. Susceptibility results showed that the resistance rate of ESBL-producing *E. coli* isolates against commonly used antimicrobial drugs was higher than the rate observed in

---

**Table 3** Bacterial character of different types of UTIs

| Total isolates | Number of Gram-negative bacteria (%)* | Number of *E. coli* (%†) | Number of ESBL positive *E. coli* (%‡) |
|----------------|---------------------------------------|--------------------------|---------------------------------------|
| Acute uncomplicated cystitis | 96 | 68 (70.83) | 51 (53.13) | 25 (49.02%) |
| Recurrent UTIs | 42 | 29 (69.05) | 21 (50.00) | 12 (57.14%) |
| Complicated UTIs | 37 | 19 (51.35) | 15 (40.54) | 9 (60.00%) |

*Percentages are computed on the number of total bacteria. †Percentages are computed on the number of Gram-negative bacteria. ‡Percentages are computed on the number of *E. coli*.

---

**Table 4** Antibacterial activity, bacterial sensitivity, intermediate sensitivity and resistance to antibiotics commonly used against ESBL-negative and ESBL-positive *Escherichia coli*

| Antimicrobial drug | ESBL-negative *E. coli* (41 isolates) | ESBL-positive *E. coli* (46 isolates) |
|-------------------|--------------------------------------|--------------------------------------|
|                   | MIC50 | MIC90 | S% | I% | R% | MIC50 | MIC90 | S% | I% | R% |
| Fosfomycin tromethamine* | 0.125 | 0.05 | 95.1 | 4.9 | 0.0 | 0.125 | 0.128 | 87.0 | 8.7 | 4.3 |
| Levofloxacin | 1 | 16 | 61.0 | 4.9 | 34.1 | 8 | 32 | 21.7 | 15.3 | 63.0 |
| Moxifloxacin | 0.5 | 32 | – | – | – | 16 | 64 | – | – | – |
| Cefdinir | 0.25 | 2 | 87.8 | 2.4 | 9.8 | 256 | >256 | 4.3 | 2.2 | 93.5 |
| Cefixime | 0.5 | 2 | 82.9 | 9.8 | 7.3 | 73 | 32 | 128 | 4.3 | 6.6 | 89.1 |
| Cefaclor | 2 | 4 | 90.2 | 2.5 | 7.3 | >256 | >256 | 2.2 | 2.1 | 95.7 |
| Cefprozil | 2 | 8 | 90.2 | 0.0 | 9.8 | >256 | >256 | 2.2 | 2.1 | 95.7 |
| Cefuroxime | 4 | 16 | 82.9 | 7.3 | 9.8 | >256 | >256 | 0.0 | 0.0 | 100.0 |
| Amoxicillin/clavulanic acid | 4 | 16 | 82.9 | 7.3 | 9.8 | 8 | 16 | 63.0 | 34.8 | 2.2 |
| Cefotaxime | 0.062 | 0.5 | 95.1 | 0.0 | 4.9 | 64 | 256 | 2.2 | 0.0 | 97.8 |
| Nitrofurantoin | 16 | 32 | 90.2 | 4.9 | 4.9 | 16 | 32 | 93.5 | 6.5 | 0.0 |

*Percentages are computed on the number of total bacteria. †Percentages are computed on the number of Gram-negative bacteria. ‡Percentages are computed on the number of *E. coli*.

* Determination of the breakpoint of fosfomycin tromethamine to Enterobacteriaceae (sensitivity rate ≤64 mg/L; resistance rate ≥256 mg/L).

---

Qiao L-D, Chen S, Yang Y, et al. BMJ Open 2013;3:e004152. doi:10.1136/bmjopen-2013-004152
ESBL-negative *E. coli* isolates. We thus consider that in the treatment of complicated UTIs, antibiotics should be indicated based on susceptibility results.

Our findings showed a good antibacterial activity of fosfomycin tromethamine against both ESBL-negative and ESBL-producing *E. coli*, with bacterial sensitivity rates of 95.1% and 87% and resistance rates of 0% and 4.3%, respectively. The antibacterial effect of this compound on ESBL-producing *E. coli* was slightly inferior to nitrofurantoin but superior to the other tested drugs, and consistent with previously published findings. In addition, a significant antibacterial activity was demonstrated against *K. pneumoniae*. However, empirical treatment with fosfomycin tromethamine and nitrofurantoin is only indicated in uncomplicated UTIs.

In our study, coagulase-negative staphylococci were the major Gram-positive pathogens identified. Initially considered as part of commensal flora and culture contaminants, since 1970 this type of staphylococci has been recognised as an aetiologic agent in a variety of infections. The main virulence factor is mucilage polysaccharide (biofilm) production facilitating their adhesion to smooth surfaces (such as the uroepithelium) and providing resistance against antibiotics and phagocytosis. In our study, Gram-positive bacteria were isolated more frequently in samples from cases with complicated UTIs than in samples from cases with uncomplicated UTIs. Furthermore, *S. epidermidis* was more frequently identified in women, and *E. faecalis* was more frequently identified in men than in women. These gender differences observed in the aetiology of UTIs are similar to those found in other studies.

### Table 5

| Antimicrobial drug                        | *K. pneumoniae* (9 isolates) | *Proteus* spp (9 isolates) |
|-------------------------------------------|-----------------------------|---------------------------|
|                                          | MIC<sub>50</sub> | MIC<sub>90</sub> | S%  | I%  | R%  | MIC<sub>50</sub> | MIC<sub>90</sub> | S%  | I%  | R%  |
| Fosfomycin tromethamine*                  | 1               | 32             | 100.0 | 0.0 | 0.0 | 1 >256         | 55.6             | 22.2 | 22.2 |
| Levofloxacin                              | 0.125 ≥256     | 66.7           | 33.3 | 0.0 | 0.0 | 1 >256         | 55.6             | 11.1 | 33.3 |
| Moxifloxacin                              | 0.062 ≥256     | –             | –    | –   | –   | 8             | 64               | –    | –    |
| Cefdinir                                  | 1 ≥256         | 44.4           | 55.6 | 0.0 | 0.0 | 256           | 44.4             | 0.0  | 44.4 |
| Cefixime                                  | 2 >256         | 11.2           | 44.4 | 8.0 | 31  | 8             | 64               | –    | –    |
| Cefaclor                                  | 256 >256       | 44.4           | 0.0  | 55.6 | >256 | >256         | 44.4             | 0.0  | 55.6 |
| Cefprozil                                 | >256 ≥256      | 44.4           | 0.0  | 55.6 | >256 | >256         | 44.4             | 0.0  | 55.6 |
| Cefuroxime                                | 64 >256        | 44.4           | 0.0  | 55.6 | 128 | >256         | 44.4             | 0.0  | 55.6 |
| Amoxicillin/clavulanic acid               | 8 16           | 66.7           | 33.3 | 0.0 | 64  | 16            | 44.4             | 44.5 | 11.1 |
| Cefotaxime                                | 2 128          | 44.4           | 11.2 | 44.4 | 0.125 | 64             | 66.7             | 0.0  | 33.3 |
| Nitrofurantoin                            | 32 66.7        | 11.1           | 64   | –    | –    | 64            | 11.1             | 77.8 | 11.1 |

* Determination of the breakpoint of fosfomycin tromethamine to Enterobacteriaceae (sensitivity rate ≤64 mg/L; resistance rate >256 mg/L).

### Table 6

| Antimicrobial drug | *Staphylococcus* spp (26 isolates) | *S. epidermidis* (16 isolates) | *E. faecalis* (15 isolates) |
|--------------------|------------------------------------|--------------------------------|-----------------------------|
|                    | MIC<sub>50</sub> | MIC<sub>90</sub> | S%  | I%  | R%  | MIC<sub>50</sub> | MIC<sub>90</sub> | S%  | I%  | R%  | MIC<sub>50</sub> | MIC<sub>90</sub> | S%  | I%  | R%  |
| Fosfomycin tromethamine* | 0.25 32 | 96.2 | 0.0 | 3.8 | 0.25 0.5 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Levofloxacin       | 0.5 128 | 50.0 | 0.0 | 50.0 | 4 128 | 43.8 | 0.0 | 56.2 | 8 | 32 | 40.0 | 0.0 | 60.0 |
| Moxifloxacin       | 0.125 16 | 50.0 | 23.1 | 26.9 | 1 16 | 43.8 | 0.0 | 56.2 | 8 | 32 | 40.0 | 0.0 | 60.0 |
| Cefdinir           | 0.5 >256 | 61.5 | 11.6 | 26.9 | 0.5 >256 | 56.3 | 12.5 | 31.2 | 1 >256 | – | – | – | – |
| Cefixime           | 16 >256 | – | – | – | 16 >256 | – | – | – | 8 >256 | – | – | – | – |
| Cefaclor           | 4 64 | 69.2 | 19.3 | 11.5 | 4 64 | 68.8 | 18.7 | 12.5 | 8 | 64 | – | – | – | – |
| Cefprozil          | 1 32 | 88.5 | 0.0 | 11.5 | 1 32 | 87.5 | 0.0 | 12.5 | 8 | 64 | – | – | – | – |
| Cefuroxime         | 1 128 | 88.5 | 0.0 | 11.5 | 1 128 | 87.5 | 0.0 | 12.5 | 8 | 64 | – | – | – | – |
| Amoxicillin/clavulanic acid | 0.5 16 | 88.5 | – | 11.5 | 0.25 16 | 87.5 | – | 12.5 | 0.5 | 2 | – | – | – | – |
| Cefotaxime         | 2 16 | 88.5 | 7.7 | 3.8 | 2 16 | 87.5 | 12.5 | 0.0 | 2 >256 | – | – | – | – | – |
| Azithromycin       | 64 >256 | 15.4 | 0.0 | 84.6 | >256 >256 | 18.8 | 0.0 | 81.2 | >256 >256 | – | – | – | – | – |
| Nitrofurantoin     | 16 32 | 100.0 | 0.0 | 0.0 | 16 32 | 100.0 | 0.0 | 0.0 | 32 | 32 | 100.0 | 0.0 | 0.0 | 0.0 |
| Oxacillin          | 0.5 128 | 38.5 | 61.5 | 0.0 | 0.5 128 | 37.5 | – | 62.5 | – | – | – | – | – | – |

* Determination of the breakpoint of fosfomycin tromethamine to Enterobacteriaceae (sensitivity rate ≤64 mg/L; resistance rate >256 mg/L).

I, intermediate; MIC, minimal inhibitory concentration; R, resistant; S, susceptible.
UTIs should be considered in the selection of antibiotics. In our population, susceptibility results showed that *S. epidermidis* had a high-resistance rate to levofloxacin (56.2%), but a moderate resistance rate to second-generation and third-generation cephalosporin (12.5%). Fosfomycin tromethamine demonstrated a larger antibacterial activity on coagulase-negative staphylococci than other tested antibiotics. For *S. epidermidis*, MIC50 and MIC90 values were 0.25 and 0.5 mg/L, respectively, and sensitivity rates were up to 100%. The rate of resistance of *E. faecalis* against levofloxacin was 60%, while the rate of sensitivity for fosfomycin tromethamine and nitrofurantoin was 100%, with MIC values between 8 and 32 mg/L. These results are consistent with those published by Perri et al., who reported that 51 of the 52 *Enterococcus faecium* and all *E. faecalis* isolates tested were susceptible or had intermediate susceptibility to fosfomycin.

**CONCLUSION**

The results of this multicenter study showed that ESBL-producing *E. coli* is the main pathogen causing symptomatic UTIs in this Chinese population. Of concern is that the resistance rate of this pathogen against commonly used antibiotics has increased. Fosfomycin tromethamine and nitrofurantoin showed a good antibacterial activity against identified pathogens, and thus can be considered for use as empirical treatment in uncomplicated UTIs. However, the mechanism on bacterial resistance is complex and diverse, and the phenomenon of multidrug-resistant bacteria has become a global burden. Susceptibility testing is a valuable tool to help in the selection of antibiotic treatment.

**Author affiliations**

1. Department of Urology, Beijing Tongren Hospital Capital Medical University, Beijing, China
2. Department of Urology, Beijing Cancer Hospital, Beijing, China
3. Department of Urology, Peking University First Hospital, Beijing, China
4. Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China
5. Department of Urology, Peking University Shougang Hospital (Jieping Wu Urology Center), Beijing, China
6. Department of Urology, Peking University People’s Hospital, Beijing, China
7. Department of Urology, Second Affiliated Hospital of Tianjin Medical University, Tianjin, China
8. Department of Urology, First Affiliated Hospital of China Medical University, Shenyang, China
9. Department of Urology, Qilu Hospital of Shandong University, Jinan, China
10. Department of Urology, Hubei Tongji Hospital, Wuhan, China
11. Department of Urology, Hunan Xiangya Second Hospital, Changsha, China
12. Department of Urology, Shanghai Changzheng Hospital, Shanghai, China
13. Department of Urology, Zhongda Hospital affiliated to Southeast University, Nanjing, China
14. Department of Urology, Beijing Friendship Hospital Capital Medical University, Beijing, China

**Acknowledgements** The authors would like to thank all study participants and the general practitioners, study nurses and personnel who contributed to this study. They wish to acknowledge the support provided by Linyu Li and Jinghan Zhang. They also thank Juliette Gray and Adriana Rusu (XPE Pharma & Science) for editorial support.

**Contributors** SC and L-DQ designed research and defined the research theme; L-DQ, YY, KZ, H-FG, BY, Y-JN, WY, B-KS, W-MY, X-KZ, X-FG, MC and YT performed the research. BZ carried out the laboratory experiments, YT and L-DQ analysed the data and interpreted the results. All authors participated in the writing of the article and have read and approved the manuscript.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Patient consent** Obtained.

**Ethics approval** The Ethics Committee of Beijing Tongren Affiliated Hospital of Capital Medical University.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**REFERENCES**

1. Stamm WE, Norby SR. Urinary tract infections: disease panorama and challenges. *J Infect Dis* 2001;183(Suppl 1):S1–4.
2. Foxman B, Barlow R, d’Arcy H, et al. Urinary tract infection: estimated incidence and associated costs. *Ann Epidemiol* 2000;10:509–15.
3. Carlson KJ, Mulley AG. Management of acute dysuria: a decision analysis model of alternative strategies. *Ann Intern Med* 1985;102:244–9.
4. Kunin CM. Urinary tract infections in females. *Clin Infect Dis* 1994:18:1–10.
5. Engel JD, Schaeffer AJ. Evaluation of and antimicrobial therapy for recurrent urinary tract infections in women. *Urol Clin North Am* 1998:25:685–701.
6. Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. *Am J Epidemiol* 2000;151:1194–205.
7. Foxman B, Freirichs RR. Epidemiology of urinary tract infection. II. Diet, clothing, and urination habits. *Am J Public Health* 1985:75:1314–17.
8. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity and economic costs. *Am J Med* 2002;113(Suppl 1A):S5–S13.
9. Jiangqiao W, Xueping W, Yujuan L. Nosocomial infection point-prevalence survey in three consecutive years. *Chin J Infect Control* 2006:5:19–34.
10. Jinxian W, Xiaoling Z, Liya Y. A nosocomial infection point-prevalence survey: results and analysis. *Chinese J Nosocomiol* 2005:15:1119–20.
11. Talan D, Stamm W, Hooton T, et al. Comparison of ciprofloxacin (7days) and trimethoprim-sulfamethoxazole (14days) for acute uncomplicated pyelonephritis in women: a randomized trial. *JAMA* 2000:283:1583–90.
12. Qi HM, Lv Y, Qian X. Ministry of Health National Antimicrobial Resistant Investigation Net 2010 annual report: bacterial resistances monitor of women urine samples. *Chinese J Clin Pharmacol* 2011:27:913–18.
13. Zheng B, Lv Y. Ministry of Health National Antimicrobial Investigation Net 2010 report: bacterial distribution and resistance in urinary tract infections in male. *Chinese J Clin Pharmacol* 2011:27:905–12.
14. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement*. CLSI document M100-S20. Wayne: CLSI, 2011.
15. Sanders CC, Barry AL, Washington JA, et al. Detection of extended spectrum beta-lactamases producing members of family Enterobacteriaceae with the Vitek ESBL test. *J Clin Microbiol* 1996;34:2997–3001.
16. Lei G, Yonghong X. 2006–2007 Mohnarin report:Bacterial distribution and resistance in urinary tract infections. *Chinese J Antibiotics* 2008:33:586–634.
17. Khan AU, Zaman MS. Multiple drug resistance pattern in Urinary Tract Infection patients in Aligarh. *Biomed Res* 2006;17:179–81.
18. Mishra MP, Debaka NK, Padhy RN, et al. Surveillance of multidrug resistant uropathogenic bacteria in hospitalized patients in Indian. *Asian Pac J Trop Biomed* 2013:3:315–24.
19. Mukherjee M, Basu S, Mukherjee SK, et al. Multidrug-resistance and extended spectrum beta-lactamase production in uropathogenic E. Coli which were isolated from hospitalized patients in Kolkata, India. J Clin Diagn Res 2013;7:449–53.

20. Odongo CO, Anywar DA, Luryamamoi K, et al. Antibiotics from community-acquired uropathogens in Gulu, northern Uganda—a cross-sectional study. BMC Infect Dis 2013;13:193.

21. Guangying Y, Xueyin Z, Anrong L. Development of a novel test identifying extended-spectrum beta lactamase producing strains relative to resistant plasmids. Chin J Microecol 2002; 14:89–90.

22. Hua Y, Hua L, Yingjun Y. Distribution of pathogens and resistance detection in urinary infection. Chinese J Nosocomiol 2003;13:982–4.

23. Haishen K, Baoguan W, Yi G. Drug resistance of Pneumonia klebsiella and E. coli to ultra wide spectrum Beta-lactam enzyme. Chinese J LabMed 2000;1:23–5.

24. Maraki S, Samonis G, Rafailidis PI, et al. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 2009;53:4508–10.

25. Piette A, Verschaeren G. Role of coagulase-negative staphylococci in human disease. Vet Microbiol 2006;134:45–54.

26. Huebner J, Goldmann DA. Coagulase-negative staphylococci: role as pathogens. Annu Rev Med 1999;50:223–36.

27. O’Gara JP, Humphreys H. Staphylococcus epidermidis biofilms: importance and implications. J Med Microbiol 2001;50:582–7.

28. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318–22.

29. Mack D, Davies AP, Harris LG, et al. Microbial interactions in Staphylococcus epidermidis biofilms. Anal Bioanal Chem 2001;377:399–408.

30. Perri MB, Hershberger E, Ionescu M, et al. In vitro susceptibility of vancomycin-resistant Enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002;42:269–71a.